Cohen I, Altaras M M, Shapira J, Tepper R, Cordoba M, Figer A, Zalel Y, Dror Y, Beyth Y
Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar Saba, Israel.
Gynecol Obstet Invest. 1997;43(1):60-3. doi: 10.1159/000291821.
In an attempt to assess the hypothesis that different endometrial sites may respond differently to tamoxifen exposure in postmenopausal women, hysteroscopic selected endometrial histology was investigated in 175 postmenopausal breast cancer patients who received continuous treatment with tamoxifen, and in 27 similar patients not treated with tamoxifen who served as controls. In the tamoxifen-treated patients 14 (8.0%) developed endometrial polyps. Of 14 patients, 8 (57.2%) each displayed atrophic endometrium in the same histologic specimen, 5 (35.7%) each had coexisting simple hyperplasia, and 1 (7.1%) other had complex hyperplasia. Another 21 (12.0%) developed simple or complex hyperplasia. The endometrial hyperplasia coexisted with atrophic endometrium in all these patients. All these lesions were selectively identified by hysteroscopic examination prior to the endometrial biopsy. In the control group 3 (11.0%) had simple hyperplasia and 2 (7.4%) had endometrial polyps. The above results support the hypothesis that the endometrium of postmenopausal breast cancer patients on tamoxifen treatment may possess different responses to tamoxifen exposure.
为了评估绝经后女性不同子宫内膜部位对他莫昔芬暴露可能有不同反应这一假设,我们对175例接受他莫昔芬持续治疗的绝经后乳腺癌患者以及27例未接受他莫昔芬治疗的类似患者(作为对照)进行了宫腔镜下选择的子宫内膜组织学研究。在接受他莫昔芬治疗的患者中,14例(8.0%)发生了子宫内膜息肉。在这14例患者中,8例(57.2%)在同一组织学标本中均表现为萎缩性子宫内膜,5例(35.7%)同时存在单纯性增生,1例(7.1%)存在复杂性增生。另外21例(12.0%)发生了单纯性或复杂性增生。所有这些患者的子宫内膜增生均与萎缩性子宫内膜并存。所有这些病变在子宫内膜活检前均通过宫腔镜检查被选择性地识别出来。在对照组中,3例(11.0%)有单纯性增生,2例(7.4%)有子宫内膜息肉。上述结果支持这样的假设,即接受他莫昔芬治疗的绝经后乳腺癌患者的子宫内膜对他莫昔芬暴露可能有不同反应。